New institute to study RNA medicine; Alnylam adds to board of directors;

> The Cancer Center at Beth Israel Deaconess Medical Center in Boston launched a new Institute for RNA Medicine. Story

> Alnylam Pharmaceuticals ($ALNY) added Amy Schulman to its board of directors. Release

> Ophthalmology company Icon Bioscience completed enrollment of its Phase III trial for an injected, sustained-release formulation of the anti-inflammatory agent dexamethasone following cataract surgery. Release

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.